Literature DB >> 17618306

The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.

C J Fowler1.   

Abstract

The development of sensitive analytical methods for measurement of endocannabinoids, their metabolites, and related lipids, has underlined the complexity of the endocannabinoid system. A case can be made for an 'endocannabinoid soup' (akin to the inflammatory soup) whereby the net effect of a pathological state and/or a pharmacological intervention on this system is the result not only of changes in endocannabinoid levels but also of their metabolites and related compounds that affect their function. With respect to the metabolism of anandamide and 2-arachidonoylglycerol, the main hydrolytic enzymes involved are fatty acid amide hydrolase and monoacylglycerol lipase. However, other pathways can come into play when these are blocked. Cyclooxygenase-2 derived metabolites of anandamide and 2-arachidonoylglycerol have a number of properties, including effects upon cell viability, contraction of the cat iris sphincter (an effect mediated by a novel receptor), mobilization of calcium and modulation of synaptic transmission. Nonsteroidal anti-inflammatory agents, whose primary mode of action is the inhibition of cyclooxygenase, can also interact with the endocannabinoid system both in vitro and in vivo. Other enzymes, such as the lipoxygenase and cytochrome P450 oxidative enzymes, can also metabolize endocannabinoids and produce biologically active compounds. It is concluded that sensitive analytical methods, which allow for measurement of endocannabinoids and related lipids, should provide vital information as to the importance of these alternative metabolic pathways when the primary hydrolytic endocannabinoid metabolizing enzymes are inhibited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618306      PMCID: PMC2190012          DOI: 10.1038/sj.bjp.0707379

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  69 in total

1.  Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine.

Authors:  Devorah Matas; Ana Juknat; Maciej Pietr; Yael Klin; Zvi Vogel
Journal:  J Biol Chem       Date:  2007-01-16       Impact factor: 5.157

2.  Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides.

Authors:  Natasha T Snider; Andrei M Kornilov; Ute M Kent; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2007-02-01       Impact factor: 4.030

3.  Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.

Authors:  D F Woodward; A H Krauss; J W Wang; C E Protzman; A L Nieves; Y Liang; Y Donde; R M Burk; K Landsverk; C Struble
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

4.  Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?

Authors:  Christian Berger; Patricia C Schmid; Wolf-Ruediger Schabitz; Margit Wolf; Stefan Schwab; Harald H O Schmid
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

5.  Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry.

Authors:  Allan Weber; Jinsong Ni; Kah-Hiing John Ling; Andrew Acheampong; Diane D-S Tang-Liu; Robert Burk; Benjamin F Cravatt; David Woodward
Journal:  J Lipid Res       Date:  2004-01-16       Impact factor: 5.922

6.  Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.

Authors:  Sandra Holt; Ben Paylor; Linda Boldrup; Kirsi Alajakku; Séverine Vandevoorde; Anna Sundström; Maria Teresa Cocco; Valentina Onnis; Christopher J Fowler
Journal:  Eur J Pharmacol       Date:  2007-03-07       Impact factor: 4.432

7.  Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism.

Authors:  I Matias; J Chen; L De Petrocellis; T Bisogno; A Ligresti; F Fezza; A H-P Krauss; L Shi; C E Protzman; C Li; Y Liang; A L Nieves; K M Kedzie; R M Burk; V Di Marzo; D F Woodward
Journal:  J Pharmacol Exp Ther       Date:  2004-02-02       Impact factor: 4.030

8.  Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus.

Authors:  Jimok Kim; Bradley E Alger
Journal:  Nat Neurosci       Date:  2004-06-06       Impact factor: 24.884

9.  Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells.

Authors:  Giulio G Muccioli; Cong Xu; Emma Odah; Eiron Cudaback; Jose Antonio Cisneros; Didier M Lambert; María Luz López Rodríguez; Sandra Bajjalieh; Nephi Stella
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

10.  Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia.

Authors:  Joseph R Ghilardi; Camilla I Svensson; Scott D Rogers; Tony L Yaksh; Patrick W Mantyh
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

View more
  32 in total

1.  Cannabinoids and their actions.

Authors:  S P H Alexander; M Randall
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 2.  The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1.

Authors:  C J Fowler; P S Naidu; A Lichtman; V Onnis
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

Review 3.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

Review 4.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 5.  Endocannabinoids and cardiac contractile function: pathophysiological implications.

Authors:  Sándor Bátkai; Pál Pacher
Journal:  Pharmacol Res       Date:  2009-08       Impact factor: 7.658

6.  Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids.

Authors:  Demetris P Papahatjis; Victoria R Nahmias; Spyros P Nikas; Marion Schimpgen; Alexandros Makriyannis
Journal:  Chemistry       Date:  2010-04-06       Impact factor: 5.236

Review 7.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

8.  Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.

Authors:  Andrew J Kwilasz; Rehab A Abdullah; Justin L Poklis; Aron H Lichtman; Sidney S Negus
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

Review 9.  Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.

Authors:  May Hamza; Raymond A Dionne
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.